Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MPTP parkinsonism.

Literature DB >> 6437573

MPTP parkinsonism.

A Williams.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1984 PMID： 6437573 PMCID： PMC1443637 DOI： 10.1136/bmj.289.6456.1401

Source DB: PubMed Journal: Br Med J (Clin Res Ed) ISSN： 0267-0623

× No keyword cloud information.

12 in total

1. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

Authors: J W Langston; P A Ballard
Journal: N Engl J Med Date: 1983-08-04 Impact factor: 91.245

2. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.

Authors: J W Langston; P Ballard
Journal: Can J Neurol Sci Date: 1984-02 Impact factor: 2.104

3. Brain peroxidase and catalase in Parkinson disease.

Authors: L M Ambani; M H Van Woert; S Murphy
Journal: Arch Neurol Date: 1975-02

4. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors: G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal: Psychiatry Res Date: 1979-12 Impact factor: 3.222

5. Aetiology of Parkinson's disease.

Authors: D B Calne; J W Langston
Journal: Lancet Date: 1983 Dec 24-31 Impact factor: 79.321

6. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

Authors: J W Langston; L S Forno; C S Rebert; I Irwin
Journal: Brain Res Date: 1984-02-06 Impact factor: 3.252

7. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man.

Authors: R S Burns; S P Markey; J M Phillips; C C Chiueh
Journal: Can J Neurol Sci Date: 1984-02 Impact factor: 2.104

8. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors: R S Burns; C C Chiueh; S P Markey; M H Ebert; D M Jacobowitz; I J Kopin
Journal: Proc Natl Acad Sci U S A Date: 1983-07 Impact factor: 11.205

9. Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine.

Authors: R Heikkila; G Cohen
Journal: Science Date: 1971-06-18 Impact factor: 47.728

10. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease.

Authors: M J Bannon; M Goedert; B Williams
Journal: Biochem Pharmacol Date: 1984-09-01 Impact factor: 5.858

8 in total

MPTP parkinsonism.

1. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

2. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.

3. Brain peroxidase and catalase in Parkinson disease.

4. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

5. Aetiology of Parkinson's disease.

6. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

7. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man.

8. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

9. Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine.

10. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease.

1. In search of the causes of Parkinson's disease, seasons 1 to 4.

2. Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

3. Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity.

Review 4. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.

5. Molecular and neurochemical mechanisms in PD pathogenesis.

6. Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.

Review 7. Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase.

8. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.